UnitedHealth's Calm And Steady 2026 Guidance

Long-term investors secretly love the kind of update UnitedHealth just served up. Their recently released 2026 adjusted earnings guidance clears expectations, even if it does so with a modest and sensible stride. The company said it expects 2026 adjusted profit per share above $17.75, slightly edging past Wall Street’s consensus and framing the outlook as part of CEO Stephen Hemsley’s effort to steady the ship after a turbulent stretch.

UnitedHealth is still talking about growth in 2026, while acknowledging where the work remains. The company flagged continued Medicaid pressure, saying payment rates haven’t kept up with rising costs, and noted it has scaled back Medicare Advantage offerings — a reminder that even the industry’s heavyweight is being picky about where it wants to compete.

UnitedHealth’s adjusted medical care ratio rose to 88.9% in 2025 from 85.5% in 2024, reflecting funding and cost dynamics the company called out, including reduced Medicare funding, Inflation Reduction Act effects, and higher healthcare expenses. Still, the quarter itself came in essentially on-script when Q4 adjusted EPS was $2.11 versus the $2.10 expected.

Health insurance stocks as a whole traded lower after the U.S. proposed only a 0.09% average increase in Medicare Advantage payments for 2027, a figure that disappointed the market. Investors can file that under "headline risk that hits sentiment", while also noting UnitedHealth just told you—again—that it plans to keep playing offense in 2026 anyway.

Disclaimer: This content is for informational and entertainment purposes only and does not constitute financial or investment advice. The information provided may be outdated or contain inaccuracies. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Investing involves risk, including the potential loss of principal. Unless explicitly stated otherwise, neither Equiscreen, LLC nor its beneficial owners hold any financial interest in the companies mentioned in our articles, and we do not receive compensation for including them. Equiscreen, LLC and its beneficial owners may buy or sell securities of any company referenced in our content at any time and without prior notice, and nothing published by Equiscreen, LLC should be interpreted as a recommendation to buy, sell, or hold any security. Any paid content or income-related materials will be clearly identified as “Sponsored” or “Advertorial,” and corresponding income disclosures can be found at the bottom of the page. For additional information, please contact [email protected].

Top Gainers

Top Losers

U.S. Commodities

2234 N Federal Hwy # 1022
Boca Raton, FL 33431

(561) 264-5726